华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02552 华领医药-B

未开盘 08-13 16:08:14

2.690

+0.055

+2.09%

最高2.735	最低2.625	成交量182.80万
今开2.625	昨收2.635	日振幅4.17%
总市值28.43亿	流通市值28.43亿	总股本10.57亿
成交额492.16万	换手率0.17%	流通股本10.57亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02552","market":"HK","secType":"STK","nameCN":"华领医药-B","latestPrice":2.69,"timestamp":1786608494005,"preClose":2.635,"halted":0,"volume":1828000,"delay":0,"changeRate":0.02087286527514238,"floatShares":1057000000,"shares":1057000000,"eps":1.2799510330918995,"marketStatus":"未开盘","change":0.055,"latestTime":"08-13 16:08:14","open":2.625,"high":2.735,"low":2.625,"amount":4921645,"amplitude":0.041746,"askPrice":2.7,"askSize":17000,"bidPrice":2.69,"bidSize":13000,"shortable":3,"etf":0,"ttmEps":1.348602952139556,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":0,"adr":0,"listingDate":1536854400000,"exchange":"SEHK","adjPreClose":2.635,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":1.0310208685319842,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02552","defaultTab":"news","newsList":[{"id":"1153659463","title":"华领医药-B（02552）将于8月20日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1153659463","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153659463?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:25","pubTimestamp":1786353950,"startTime":"0","endTime":"0","summary":"华领医药-B（02552）8月10日公告称，董事会拟于2026年8月20日（星期四）召开会议，审议并通过本集团截至2026年6月30日止六个月的中期业绩及相关公告，并处理其他事项。\n根据公告，董事会成员包括执行董事陈力博士（亦为行政总裁）、林洁诚先生及张怡博士；非执行董事Robert Taylor Nelsen先生；以及独立非执行董事William Robert Keller先生、徐耀华先生及张耀樑先生。\n公司表示，相关业绩公告将在董事会会议后刊发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148654352","title":"华领医药-B上半年预计亏损3020万元 营收增长毛利率改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1148654352","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148654352?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:44","pubTimestamp":1786067071,"startTime":"0","endTime":"0","summary":"华领医药-B（2552.HK）8月7日发布公告，预计2026年上半年将录得亏损约3020万元人民币。尽管亏损持续，但公司同时透露，期内营收实现增长，毛利率亦有所改善。\n公告显示，华领医药-B在2026年上半年业绩中，净亏损预计为3020万元。不过，公司强调，营收较去年同期有所提升，且毛利率表现向好。这一趋势反映出公司在产品商业化及成本控制方面取得了一定进展。\n作为一家专注于创新药研发的生物科技公司，华领医药-B的核心产品已进入市场，并逐步产生收入。此次业绩预告虽显示亏损，但营收增长及毛利率改善的信号，或为市场带来积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667676","title":"华领医药-B预计上半年亏损3020万元，同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667676","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667676?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:50","pubTimestamp":1786063800,"startTime":"0","endTime":"0","summary":"8月7日，华领医药-B（02552）发布公告，预计截至2026年6月30日止六个月将录得亏损约3020万元，相较于2025年同期的期内溢利约11.84亿元，亏损幅度显著。业绩变动的主要原因是终止与拜耳的合约，导致未能计入2025年同期的其他收入，包括一次性解除合约负债约12.44亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073834583133.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073834583133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02552","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196528708","title":"华领医药-B（02552）发盈警：上半年预亏3020万元，主因去年一次性收益缺失","url":"https://stock-news.laohu8.com/highlight/detail?id=1196528708","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196528708?lang=zh_cn&edition=full","pubTime":"2026-08-07 06:16","pubTimestamp":1786054567,"startTime":"0","endTime":"0","summary":"\\n\\n公司表示，业绩转亏主要由于2025年同期确认了终止拜耳合约所产生的一次性其他收入约12.44亿元，而本报告期未再录得相关收益。\\n\\n剔除该非经常性项目影响后，集团预计本报告期经调整亏损将较2025年同期的59.6百万元收窄约29.4百万元，主要由于收入增加及毛利率改善。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131061623","title":"华领医药-B更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1131061623","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131061623?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:47","pubTimestamp":1786006061,"startTime":"0","endTime":"0","summary":"华领医药-B于2026年8月6日发布截至2026年7月31日的股份变动月报。公告显示，公司法定注册股本维持在2,000,000,000股，面值每股USD 0.001，注册股本总额保持USD 2,000,000；报告期末已发行普通股总数为1,056,605,016股，未发生新增发行或库存股变动，公司已满足相关公众持股量要求。期间亦无其他认股权证、可换股票据及其他股份回购或注销活动，公司股本结构整体保持稳定。本次公告由公司秘书欧阳丽妮签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157908311","title":"华领医药-B更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1157908311","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157908311?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:52","pubTimestamp":1783414360,"startTime":"0","endTime":"0","summary":"华领医药-B于2026年7月7日发布截至2026年6月30日的月报表。报告显示，公司法定/注册股本维持在2,000,000,000股，面值USD 0.001，合计USD 2,000,000，与上月底持平。已发行股份方面，截至2026年6月30日，公司已发行股本为1,056,605,016股，较上月底的1,056,605,016股无变化；公司并无库存股份，月内未发生任何新增发行、购回或注销活动，股本总数保持稳定。在股份激励方面，截至本月末，华领医药-B首发后购股权计划共计77,964,854份期权，月内无行使、授出、失效或注销记录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648741577","title":"港股异动 | 华领医药-B(02552.HK)涨超10% 首创新药多格列艾汀获批登陆澳门 协同大昌华嘉拓展大湾区市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2648741577","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648741577?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:46","pubTimestamp":1782978384,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1161","06978","02552","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534032","title":"港股异动 | 华领医药-B(02552)涨超8% 多格列艾汀多项研究成果亮相ADA GK Charger系统化医学持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534032","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647534032?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:22","pubTimestamp":1782703352,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华领医药-B涨超8%，截至发稿，涨8.04%，报2.15港元，成交额345.01万港元。消息面上，近日，华领医药在第86届美国糖尿病协会科学年会上公布了全球首创葡萄糖激酶激活剂多格列艾汀的一系列重磅研究成果，覆盖联合用药协同效应、大规模真实世界证据及AI精准诊疗工具，进一步巩固了其在血糖稳态研究领域的全球领先地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02552","BK1191","BK4588","BK1574","GK","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340326","title":"港股异动 | 华领医药-B(02552.HK)涨超8% 多格列艾汀多项研究成果亮相ADA GK Charger系统化医学持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647340326?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:22","pubTimestamp":1782703352,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02552","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646587380","title":"华领医药-B(02552.HK)：张怡获委任为提名委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2646587380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646587380?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:32","pubTimestamp":1782376371,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02552","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642945579","title":"华领医药(02552)亮相ADA年会：多格列艾汀多项研究成果发布 夯实血糖稳态全球领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2642945579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642945579?lang=zh_cn&edition=full","pubTime":"2026-06-09 10:31","pubTimestamp":1780972290,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月9日，华领医药在第86届美国糖尿病协会科学年会上公布了全球首创葡萄糖激酶激活剂多格列艾汀的一系列重磅研究成果，覆盖联合用药协同效应、大规模真实世界证据及AI精准诊疗工具，进一步巩固了其在血糖稳态研究领域的全球领先地位。其中，口头报告首次证实多格列艾汀联合口服小分子GLP-1受体激动剂orforglipron具有协同作用。该研究纳入2024例2型糖尿病患者，随访52周。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109748759","title":"华领医药-B5月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1109748759","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109748759?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:47","pubTimestamp":1780562872,"startTime":"0","endTime":"0","summary":"华领医药-B于2026年6月4日公布2026年5月股份变动月报表，报告期截至2026年5月31日。报告显示，截至本月底，公司注册股本为2,000,000,000股，面值每股0.001美元，总额2,000,000美元；已发行股份总数为1,056,605,016股，与上月底持平，期间无新增发行、回购或注销股份。库存股份数目为0股，亦无变化。期内并未因行使期权而发行新股或发生库存股份转让。截至2026年5月31日，公司股本结构保持稳定，无新增发行、购回或注销活动。本次公告由公司秘书欧阳丽妮签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636836807","title":"华领医药，与拜耳分手后的第一年","url":"https://stock-news.laohu8.com/highlight/detail?id=2636836807","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636836807?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:05","pubTimestamp":1779177912,"startTime":"0","endTime":"0","summary":"文｜锦缎与拜耳“分手”后的第一个完整运营年，华领医药披露了一份可喜的年报。想当年，华领医药与拜耳之间的合作，曾被视为国内创新药企与跨国药企强强联手的典范。2024年11月22日，华领医药公告称，已向拜耳发出书面通知，决定自2025年1月1日起，正式收回华堂宁在中国的全部商业化权益。华领医药交出了一份超出市场预期的答卷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1778819771593384829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02552","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634049003","title":"格隆汇个股放量排行榜 | 5月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2634049003","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634049003?lang=zh_cn&edition=full","pubTime":"2026-05-09 17:30","pubTimestamp":1778319004,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日福田股份(08196)、优博控股(08529)、大行科工(02543)、信利国际(00732)、绿茶集团(06831)、兴证国际(06058)、马可数字科技(01942)、富通科技(00465)、粤港湾控股(01396)、千百度(01028)、大酒店(00045)、希慎兴业(00014)、长和(00001)、普拉达(01913)、中国海外发展(00688)、港铁公司","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/09173057055514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01396","00819","00290","08529","01358","01942","00215","00550","01028","02552","06978","00546","00014","00117","00045","00839","00434","00688","02718","00085","00017","01828","00412","00279","00069","00010","00465","00001","02543","02632","00365","06031","00243","00669","00118","01401","00732","02511","00752","02020","01140","01083","06669","01876","00012","00813","02418","00005","00066","01113"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1138227679","title":"华领医药-B4月股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1138227679","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138227679?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:56","pubTimestamp":1778144205,"startTime":"0","endTime":"0","summary":"华领医药-B于2026年5月7日公布截至2026年4月30日的股份变动月报表。公司本月已发行股份数量共计1,056,605,016股，与上月持平，未出现新增发行、购回或库存股份变动，整体股本维持稳定。公司发布的报告显示，截至4月底，公司法定/注册股本为2,000,000,000股，面值为每股USD 0.001，对应法定/注册股本总额USD 2,000,000。公司表示，已根据香港联交所《上市规则》及相关法律规定完成本月所有股份相关事宜，并确认符合适用的公众持股量要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125993010","title":"华领医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1125993010","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125993010?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:55","pubTimestamp":1776862545,"startTime":"0","endTime":"0","summary":"华领医药-B于最新公告中表示，董事会已就股份购回计划寻求一般授权，规模最多可达公司已发行股份总数的10%。根据公告，该公司目前已发行1,056,605,016股，回购上限约为105,660,501股。董事会指出，过去12个月内，公司股价最高曾达每股4.95港元，最低曾至1.73港元。此外，公司将于2026年6月25日召开股东周年大会审议相关回购事项，并于2026年6月22日至2026年6月25日期间暂停办理股份过户登记。董事会强调，此举符合公司和股东的最佳利益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华领医药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143998052","title":"华领医药-B2025年营收大增并扭亏为盈 核心糖尿病药物加速市场覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1143998052","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143998052?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:44","pubTimestamp":1776861868,"startTime":"0","endTime":"0","summary":"华领医药-B在2025年度实现主营收入人民币4.93亿元，同比上年增长93%，主要源于dorzagliatin的销量攀升。同期毛利约人民币2.80亿元，毛利率提升至56.9%，年末银行结余及现金约人民币10.92亿元。研发开支约人民币1.45亿元，较上一年度减少32%。税前溢利同比增加542%至人民币11.06亿元，全面收益总额亦达人民币11.07亿元，标志着公司成功扭亏为盈。作为核心产品，dorzagliatin在中国内地于2025年1月起全面销售，并在糖尿病血糖管理方面取得阶段性成果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华领医药-B2025年营收大增并扭亏为盈 核心糖尿病药物加速市场覆盖","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150565203","title":"华领医药-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150565203","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150565203?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:43","pubTimestamp":1775724230,"startTime":"0","endTime":"0","summary":"华领医药-B（02552）于2026年4月9日公布了截至2026年3月31日的股份变动月报表。报告显示，公司注册股本仍为2,000,000,000股，每股面值0.001美元，对应注册股本总额2,000,000美元，与上月保持一致。\n报告期内，公司已发行股份总数保持在1,056,605,016股，未出现新增发行或回购，亦无库存股相关变动。截至3月31日，股份期权方面发生了100,000股的失效；本月底期权余量由79,139,669股减少至79,039,669股，但并未导致新增股份发行或股本变动。\n公司表示，已遵守包括香港联交所《上市规则》在内的各项法律和监管规定。该公告由公司秘书欧阳丽妮签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622438848","title":"华领医药(02552)2025年报观：从首迎年度盈利，探寻GKA龙头的长期增长逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2622438848","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622438848?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:00","pubTimestamp":1774594800,"startTime":"0","endTime":"0","summary":"截至2025年末，华堂宁已通过3000多家医院、社区卫生中心、药房和线上渠道惠及超50万名患者，商业化体系的成功得到充分验证。值得关注的是，作为全球首创GKA药物的研发企业，华领医药的领跑优势不仅在于创新产品，更在于对“商业确定性”的持续构建，2025年的两大关键进展，进一步强化了其在GKA赛道的龙头地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622816348","title":"华领医药-B早盘大涨超14% 2025年实现创纪录盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2622816348","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622816348?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:07","pubTimestamp":1774577220,"startTime":"0","endTime":"0","summary":"　　华领医药-B早盘大涨超14%，截至发稿，股价上涨14.15%，现报3.55港元，成交额1761.08万港元。　　华领医药公布2025年度业绩。报告期内，产品销量达401.1万盒，同比增长91%；净销售额达4.929亿元，同比增长93%。　　公司2025年实现创纪录盈利，税前盈利达11.064亿元；现金余额稳健，截至年末达 10.923亿元，为持续运营发展奠定坚实基础；毛利率提升至56.9%，销售开支占比从59.9%优化至33.6%，盈利能力显著增强。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-27/doc-inhskwcy5418407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1191","02552"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huamedicine.com","stockEarnings":[{"period":"1week","weight":0.1255},{"period":"1month","weight":0},{"period":"3month","weight":-0.265},{"period":"6month","weight":-0.1151},{"period":"1year","weight":-0.1873},{"period":"ytd","weight":-0.1266}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华领医药是一家主要从事用于治疗2型糖尿病的口服新药的开发及商业化的投资控股公司。该公司还从事华堂宁产品的商业化。该公司的主要产品管线Dorzagliatin或HMS5552是一种葡萄糖激酶激活剂或GKA，旨在通过恢复2型糖尿病患者的血糖稳态平衡来控制糖尿病的渐进性退行性特性。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.004737},{"month":2,"riseRate":0.5,"avgChangeRate":-0.007017},{"month":3,"riseRate":0.375,"avgChangeRate":-0.030115},{"month":4,"riseRate":0.25,"avgChangeRate":-0.049836},{"month":5,"riseRate":0.5,"avgChangeRate":0.051003},{"month":6,"riseRate":0.5,"avgChangeRate":0.021739},{"month":7,"riseRate":0.5,"avgChangeRate":0.040961},{"month":8,"riseRate":0.5,"avgChangeRate":-0.020886},{"month":9,"riseRate":0.714286,"avgChangeRate":0.034598},{"month":10,"riseRate":0.125,"avgChangeRate":-0.101466},{"month":11,"riseRate":0.5,"avgChangeRate":0.071213},{"month":12,"riseRate":0.625,"avgChangeRate":0.032299}],"exchange":"SEHK","name":"华领医药-B","nameEN":"HUA MEDICINE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华领医药-B,02552,华领医药-B股票,华领医药-B股票老虎,华领医药-B股票老虎国际,华领医药-B行情,华领医药-B股票行情,华领医药-B股价,华领医药-B股市,华领医药-B股票价格,华领医药-B股票交易,华领医药-B股票购买,华领医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}